Promoting Smoking Cessation in Lung Cancer Screening Through Proactive Treatment

NACompletedINTERVENTIONAL
Enrollment

944

Participants

Timeline

Start Date

May 10, 2019

Primary Completion Date

February 9, 2023

Study Completion Date

February 9, 2023

Conditions
Smoking ReductionTobacco UseTobacco SmokingTomographyLung DiseasesLung Neoplasms
Interventions
BEHAVIORAL

Unsigned note to provider about cessation medication prescription

For patients of providers assigned to the proactive study group, a local coordinator will review the patient's cessation medication history. If the patient is not currently being provided cessation support medication, the coordinator will enter a note for the provider about the recommended medication indicated by VA formulary guidelines.

BEHAVIORAL

Proactive Telephone Counseling from VA Quitline

Patients of providers assigned to the proactive study group will be contacted by specially trained counselors at the VA Quitline. Counselors will attempt to provide two sessions of proactive telephone support.

Trial Locations (3)

10010-5011

Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY, New York

02908-4734

Providence VA Medical Center, Providence, RI, Providence

98108-1532

VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle

All Listed Sponsors
collaborator

Fred Hutchinson Cancer Center

OTHER

lead

VA Office of Research and Development

FED

NCT03612804 - Promoting Smoking Cessation in Lung Cancer Screening Through Proactive Treatment | Biotech Hunter | Biotech Hunter